 This study proposes a new approach to treating glioblastoma, GBM, a highly aggressive form of brain cancer. The researchers used CISPR-VCAS9 technology to genetically modify human pluribotent stem cells so they could produce neutrophils with anti-GBM car constructs containing either CD3 zeta or signaling domains. These neutrophils were then used to deliver and release nanodrugs to target GBM without causing further inflammation. The results showed that this combination therapy was more effective than existing treatments, reduced off-target drug delivery, and extended the lifespans of female tumour-bearing mice. This article was authored by Yun Chang, Shu-H-L-C-A-I, Wameezah Sayahira, and others.